Tamoxifen antagonizes proliferation and invasion of estrogen receptor-negative metastatic follicular thyroid cancer cells via protein kinase C

Cancer Letters

Volumn 100, Issue 1-2, 1996, Pages 89-93

  Hoelting, Thomas ^a   Duh, Quan Yang ^b   Clark, Orlo H ^b   Herfarth, Christian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Differentiated thyroid cancer; Protein kinase C; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; STAUROSPORINE; TAMOXIFEN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; THYROID CANCER;

EID: 0030019604     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(95)04074-9     Document Type: Article

References (23)

1. Thomas, M. and Monet, T.E. (1992) Combined effects of RU 486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line. J. Clin. Endocrinol. Metab., 75, 865-870.
2. Gross, C., Yu, M., Van Herle, A.J., Giuliano, A.E. and Juillard, G.J.F. (1993) Presence of a specific antiestrogen binding site on human follicular thyroid carcinoma cell line (UCLA RO 82 W-1): inhibition by an endogenous ligand present in human serum. J. Clin. Endocrinol. Metab., 77, 1361-1366.
3. Robinson, S.P. and Jordan, V.C. (1987) Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenz-anthracene-induced rat mammary carcinoma model. Cancer Res., 47, 5386-5390.
4. Hölting, Th., Clark, O.H. and Duh, Q.Y. (1995) Tamoxifen inhibits growth, migration and invasion of human follicular and papillary thyroid cancer cells in vitro and in vivo. J. Clin. Endocrinol. Metab., 80, 308-313.
5. Hölting, Th., Tezelman, S., Siperstein, A.E., Duh, Q.Y. and Clark, O.H. (1993) Thyrotropin stimulates invasion and growth of follicular thyroid cancer cells via PKC- rather than PKA-activation. Biochem. Biophys. Res. Commun., 195, 1230-1236.
6. O'Brian, C.A., Ward, N.E. and Anderson, B.W. (1988) Role of specific interactions between protein kinase C and triphenylethylenes in inhibition of the enzyme. J. Natl. Cancer Inst., 80, 1628-1633.
7. Ambiosi-Impiombato, F.S., Parks, L.A.M. and Coon, H.G. (1980) Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc. Natl. Acad. Sci. USA, 77, 3455-3459.
8. Hölting, Th., Zielke, A., Siperstein, A.E., Clark, O.H. and Duh, Q.Y. (1994) Transforming growth factor beta 1 is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion and adhesion in follicular and papillary thyroid cancer cell lines. J. Clin. Endocrinol. Metab., 79, 806-813.
9. Jordan, V.C. and Murphy, C.S. (1990) Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev., 11, 578-610.
10. Reddel, R.R., Murphy, L.C., Hall, R.E. and Sutherland, R.L. (1985) Differential sensitivity of human breast cancer cells to the growth-inhibitory effects of tamoxifen. Cancer Res., 45, 1525-1531.
11. Cocconi, G., Bella, M., Calabresi, F., Tonato, M., Canaietti, R., Boni, C., Ceci, G., Corona, E., Costa, P., Lottici, R., Papadia, F., Sofra, M.C. and Bacchi, M. (1992) Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N. Engl. J. Med., 327, 516-523.
12. Brooks, M.D., Ebbs, S.R., Colletta, A.A. and Baum, M. (1992) Desmoid tumors treated with triphenylethylenes. Eur. J. Cancer, 28A, 1014-1018.
13. Yang, K.P., Pearson, C.E. and Samaan, N.A. (1988) Estrogen receptor and hormone responsiveness of medullary thyroid carcinoma cells in continuous culture. Cancer Res., 48, 2760-2763.
14. Weber, C.J., Marvin, M., Krekun, S., Koschitzki, T., Karp, F., Benson, M. and Feind, G.R. (1990) Effects of tamoxifen and somatostatin analogue on growth of human medullary, follicular and papillary thyroid carcinoma cell lines: tissue culture and nude mouse xenograft studies. Surgery, 109, 1065-1071.
15. Berthois, Y., Dong, X.F. and Martin, P.M. (1989) Regulation of epidermal growth factor receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7. Biochem. Biophys. Res. Commun., 159, 126-131.
16. Noguchi, S., Motomura, K, Inaji, H., Imaoka, S. and Koyama, H. (1993) Downregulation of transforming growth factor alpha by tamoxifen in human breast cancer. Cancer, 72, 131-136.
17. Butta, A., McLennan, K, Flanders, K.C., Sacks, N.P.M., Smith, I., McKinna, A., Dowsett, M., Wakefield, L.M., Sporn, M.B., Baum, M. and Colletta, A.A. (1992) Induction of transforming growth factor betal in human breast cancer in vivo following tamoxifen treatment. Cancer Res., 52, 4261-4264.
18. Manni, A., Wright, C. and Buck, H. (1991) Growth factor involvement in the multihormonal regulation of MCF-7 breast cancer cell growth in soft agar. Breast Cancer Res. Treat., 20, 43-52.
19. Bracke, M.E., Charlier, C., Bruynell, E.A, Labit, C., Mareel, M.M. and Castronovo, V. (1994) Tamoxifen restores the Ecadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype. Cancer Res., 54, 4607-4609.
20. Millon, R., Nicora, F., Muller, D., Eber, M., Klein-Soyer, C. and Abecassis, J. (1989) Modulation of human breast cancer cell adhesion by estrogens and antiestrogens. Clin. Exp. Metastasis, 7, 405-415.
21. Rowlands, M.G., Parr, I.B., McCague, R., Jarman, M. and Goddard, P.M. (1990) Variation of inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity. Biochem. Pharmacol., 49, 283-289.
22. Siperstein, A.E., Zeng, Q.H., Gum, E.T., Levin, K.E. and Clark, O.H. (1988) Adenylate cyclase activity as a predictor of thyroid tumor aggressiveness. World J. Surg., 12, 528-533.
23. Shaver, J.K., Tezelman, S., Siperstein, A.E., Duh, Q.Y. and Clark, O.H. (1993) TSH activates phospholipase C in normal and neoplastic thyroid tissue. Surgery, 114, 1064-1069.